Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin
- PMID: 29211241
- PMCID: PMC5719549
- DOI: 10.1590/0074-02760170133
Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin
Abstract
Background: The B subunit of Escherichia coli heat-labile enterotoxin (LTB) is a potent mucosal immune adjuvant. However, there is little information about LTB's potential as a parenteral adjuvant.
Objectives: We aimed at evaluating and better understanding rLTB's potential as a parenteral adjuvant using the fused R1 repeat of Mycoplasma hyopneumoniae P97 adhesin as an antigen to characterise the humoral immune response induced by this construct and comparing it to that generated when aluminium hydroxide is used as adjuvant instead.
Methods: BALB/c mice were immunised intraperitoneally with either rLTBR1 or recombinant R1 adsorbed onto aluminium hydroxide. The levels of systemic anti-rR1 antibodies (total Ig, IgG1, IgG2a, and IgA) were assessed by enzyme-linked immunosorbent assay (ELISA). The ratio of IgG1 and IgG2a was used to characterise a Th1, Th2, or mixed Th1/Th2 immune response.
Findings: Western blot confirmed rR1, either alone or fused to LTB, remained antigenic; anti-cholera toxin ELISA confirmed that LTB retained its activity when expressed in a heterologous system. Mice immunised with the rLTBR1 fusion protein produced approximately twice as much anti-rR1 immunoglobulins as mice vaccinated with rR1 adsorbed onto aluminium hydroxide. Animals vaccinated with either rLTBR1 or rR1 adsorbed onto aluminium hydroxide presented a mixed Th1/Th2 immune response. We speculate this might be a result of rR1 immune modulation rather than adjuvant modulation. Mice immunised with rLTBR1 produced approximately 1.5-fold more serum IgA than animals immunised with rR1 and aluminium hydroxide.
Main conclusions: The results suggest that rLTB is a more powerful parenteral adjuvant than aluminium hydroxide when administered intraperitoneally as it induced higher antibody titres. Therefore, we recommend that rLTB be considered an alternative adjuvant, even if different administration routes are employed.
Figures




References
-
- Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol. 1999;163(12):6448–6454. - PubMed
-
- Brewer JM. (How) do aluminium adjuvants work? Immunol Lett. 2006;101(1):10–15. - PubMed
-
- Conceição FR, Moreira AN, Dellagostin OA. A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits immune response in mice. Vaccine. 2006;24(29-30):5734–5743. - PubMed
-
- Cunha CEP, Moreira GMSG, Salvarani FM, Neves MS, Lobato FC, Dellagostin OA, et al. Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D. Vaccine. 2014;32(2):214–216. - PubMed
-
- de Haan L, Verweij WR, Holtrop M, Brands R, van Scharrenburg GJ, Palache AM, et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA-or IgG-mediated protective mucosal immunity. Vaccine. 2001;19:2898–2907. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources